<DOC>
	<DOCNO>NCT00725062</DOCNO>
	<brief_summary>RATIONALE : A donor peripheral stem cell transplant help stop growth cancer cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Once donated stem cell begin work , patient 's immune system may see remain cancer cell belong patient 's body destroy . Giving infusion donor T cell may help stop patient 's immune system reject donor 's stem cell . PURPOSE : This phase I/II trial study side effect best dose donor T cell treat patient high-risk hematologic cancer undergo donor peripheral blood stem cell transplant . Note : Only Phase I portion study perform . Due slow accrual , study close Phase II portion study .</brief_summary>
	<brief_title>Donor T Cells Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose ( MTD ) CD4+/CD25+ cell safely administer patient undergo HLA-identical sibling donor Peripheral Blood Progenitor Cell ( PBPC ) transplantation . - To determine whether CD4+ CD25+ cell safely administer patient high-risk hematologic malignancy undergo HLA-identical sibling donor PBPC transplantation . Secondary - To determine incidence grade II-IV acute graft-versus-host-disease ( GVHD ) , chronic GVHD , relapse , survival administration CD4+ CD25+ regulatory T cell patient . OUTLINE : This dose-escalation study CD4+ CD25+ donor regulatory T cell follow phase II study . All patient receive myeloablative preparative therapy GVHD prophylaxis per University Minnesota protocol UMN-MT2001-02 UMN-MT2001-10 . - First allogeneic peripheral blood progenitor cell ( PBPC ) infusion : Patients receive unmobilized , culture-expanded , CD4- CD25-positive donor regulatory T cell IV 15-60 minute assign dose day -2 . - Second allogeneic PBPC infusion : Patients undergo matched-sibling donor PBPC transplantation IV day 0 . Patients undergo blood sample collection prior commencement preparative therapy day 100 , 6 month , 1 year PBPC transplantation . Samples analyze immune reconstitution immunophenotyping functional analysis . After completion study therapy , patient follow 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<criteria>Diagnosis highrisk hematologic malignancy , include follow : Acute lymphocytic leukemia Acute myelocytic leukemia Chronic myelogenous leukemia Myelodysplastic syndrome NonHodgkin lymphoma Multiple myeloma Meet eligibility criterion coenrolled one follow University Minnesota protocol : MT200102 consist myeloablative prep ( cyclophosphamide total body irradiation ) follow HLAidentical sibling peripheral blood progenitor cell ( PBPC ) transplantation MT200110 consist nonmyeloablative prep ( cyclophosphamide , fludarabine total body irradiation ) follow HLAidentical sibling PBPC transplantation Voluntarily write informed consent Must HLAidentical sibling donor available , meet follow criterion : 12 75 year age , &gt; 40 kg body weight good health Matched recipient HLAA , B , DRB1 identical sibling match recipient Must able willing separate apheresis collection perform day 21 purpose study ( addition apheresis require transplant protocol ) Human immunodeficiency virus nucleic acid testing ( HIVNAT ) negative , Human Tlymphotropic virus 1 ( HTLV1 ) , HTLV2 negative , hepatitic B C negative Not pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>